The clinical pharmacology of bleomycin administered as an i.v. bolus has been studied in a homogeneous group of patients receiving a single regimen containing bleomycin, vinblastine, and cis dichlorodiammineplatinum(II). These studies demonstrated that in patients with creatinine clearance ≥ 35 ml/min, the serum (or plasma) terminal elimination half life of bleomycin was approximately 115 min. In patients with creatinine clearances < 25-35 ml/min, the terminal elimination half life increased exponentially as the creatinine clearance decreased. The volume of distribution was approximately 20 l, and was unaffected by changes in the creatinine clearance. The microbiologic assay and radioimmunoassay employed gave equivalent results.
|Original language||English (US)|
|Number of pages||6|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1977|
ASJC Scopus subject areas
- Cancer Research